PT-141 Peptide (Bremelanotide)
Bremelanotide, the melanocortin agonist that went all the way to FDA approval in 2019, carrying a documented blood pressure signal and a hyperpigmentation risk on its label.
Choose your pack
For research use only. Not for human or veterinary use.
What PT-141 Peptide (Bremelanotide) is
The plain-language version, first.
One of the shelf's few molecules with a genuine FDA approval, label and all.
PT-141 is bremelanotide, a cyclic seven amino acid melanocortin receptor agonist that arose as a metabolite of Melanotan 2 and acts on central melanocortin pathways rather than on peripheral blood flow. It is FDA approved and marketed as Vyleesi for hypoactive sexual desire disorder in premenopausal women.
This one made it. Full development, FDA approval, 2019, a real product name on a real pharmacy shelf under prescription.
Which makes the label public record, and the label is the most honest document ever written about this molecule.
PT-141, generically bremelanotide, is a cyclic melanocortin agonist. Its family tree matters: it descends from melanotan-II, the tanning peptide, because melanocortin receptors run several departments at once.
Same family of receptors handles pigmentation, appetite and arousal signalling, which is how a tanning project ended up producing this.
An approved drug with a research-vial twin. The approval belongs to the pharmacy product, and the label's warnings travel with the molecule either way.
What is PT-141?
Mechanism studied, not outcome promised.
Acts on melanocortin receptors in the brain, principally MC4R, rather than on smooth muscle and blood flow the way PDE5 inhibitors do.
MC1R engagement is why repeated dosing can produce focal hyperpigmentation of the face, gums and breasts, which the label notes may not resolve on stopping.
Descended from a tanning peptide, and the family resemblance never left.
Melanocortin receptors are a five-member family, and selectivity between them is the entire game.
PT-141 works the family broadly enough that its effects were never going to be single-purpose.
Descended from a tanning molecule, and the pigmentation activity did not get left behind: hyperpigmentation is on the approved label as a documented risk.
So is a blood pressure signal, transient increases documented well enough that the label restricts how often the approved product may be used and rules it out for some cardiovascular histories.
Here's the honest part, and for once a regulator wrote it for us.
The label is the mechanism section with consequences attached. It is public, it is specific, and it is the one document about this compound nobody selling it links to.
The research so far for PT-141 Peptide (Bremelanotide)
Where the evidence is thin, we say so.
A completed placebo-controlled clinical programme, an FDA approval in June 2019, and a full label with a documented adverse event profile. Very few compounds on this site have any of that.
Transient blood pressure increase and heart rate decrease after each dose. Contraindicated in uncontrolled hypertension and known cardiovascular disease. Focal hyperpigmentation with repeated use that may not resolve.
Bremelanotide was identified as a metabolite of Melanotan 2. Melanotan 2 has no approval anywhere and a case report literature. Its metabolite went through a full clinical programme and was approved by the FDA in June 2019. Same receptor family, opposite regulatory outcomes.
Approved, labelled, and the label is required reading.
A complete file, for once: phase 1 through 3, an approval, and post-market surveillance since 2019.
The trials documented modest efficacy against placebo, the blood pressure effect, the pigmentation risk, and high nausea rates. All quantified, all public.
This is what a finished evidence base looks like, and it is worth reading precisely because so little else here has one.
The approval covers a specific indication, in a specific population, under prescription. A research vial inherits none of that, while the molecule's documented risks come along regardless.
Approved is not the same as benign. The label says both things at once, and it is three clicks away on the FDA's own site.
Have a look at the vial sizes we currently have in stock.
PT-141 Peptide (Bremelanotide) specs
The chemistry, exactly as released.
Who studies PT-141 Peptide (Bremelanotide)
Who tends to order this one, and why.
A research compound does not have one audience. It has a handful of rooms where the same question keeps coming up, and the question is a different question in each of them.
Melanocortin pharmacology
MC4R signalling in the central nervous system, and how selectivity across the receptor family determines an effect profile.
Sexual medicine
The approved indication sits here, and the mechanism is central rather than vascular, which distinguishes it from the PDE5 inhibitor class.
Cardiovascular pharmacology
The transient pressor effect and heart rate decrease are documented in the approved label and drive its contraindications.
Dermatology
Focal hyperpigmentation from MC1R engagement, which the label flags as more likely with frequent dosing and in darker skin types.
Sold for laboratory research only. This is not guidance for personal use, and nothing here is a recommendation.
PT-141 Peptide (Bremelanotide) backstory
How it got here.
The University of Arizona melanocortin programme produced Melanotan 1 and Melanotan 2 as engineered alpha-MSH analogues. Melanotan 1 became an approved drug for a rare light sensitivity disorder.
Melanotan 2 was never developed at all. Bremelanotide came out of the middle of that work, as a metabolite of Melanotan 2 with activity worth pursuing separately.
It was taken through clinical development by Palatin Technologies and licensed to AMAG Pharmaceuticals. An earlier intranasal formulation was investigated and abandoned, with blood pressure effects part of the reason the programme moved to a subcutaneous autoinjector at a lower systemic exposure.
The blood pressure signal that shaped that decision is still in the approved label.
- 1
Arizona melanocortin research
The 1980s programme that produced Melanotan 1 and Melanotan 2 as engineered alpha-MSH analogues.
- 2
A metabolite with a life of its own
Bremelanotide was identified as a breakdown product of Melanotan 2 with activity worth developing separately.
- 3
FDA approval, June 2019
Developed by Palatin Technologies and licensed to AMAG, approved as Vyleesi in a single-use autoinjector for as-needed use.
Buying PT-141 Peptide (Bremelanotide) in Canada
What ships, how fast, and the paperwork.
The hard part of buying research material is almost never the compound. It is the logistics. What leaves the building, how fast it moves, and what is in the box beside the vial. Here is ours, plainly.
Same day out of British Columbia
Our building, our cold packs, our people, and nothing sitting in a customs queue while you refresh a tracking page.
Then into the fridge
Keep it cold and keep it dark. Sealed and freeze-dried it handles a rough trip without ice. Once it lands, fridge.
There is an approved label for this one
That is unusual here and it is worth using. It documents a transient blood pressure rise after each dose, contraindications in uncontrolled hypertension and known cardiovascular disease, and hyperpigmentation that may not resolve. Most compounds on this site have no such document to check.
Stuff people ask about PT-141 Peptide (Bremelanotide)
If your question is not here, email us. Real human answers.
Yes. Bremelanotide was approved by the FDA in June 2019 under the brand name Vyleesi, for acquired generalised hypoactive sexual desire disorder in premenopausal women, supplied as a single-use autoinjector for as-needed use. It is one of very few compounds on this site with a completed clinical programme behind it.
It is a metabolite of it. Bremelanotide was identified as a breakdown product of Melanotan 2 with activity worth developing on its own. Melanotan 2 was never developed by any sponsor and has no approval anywhere. Its metabolite went through full clinical development and was approved. Same receptor family, opposite outcomes.
The approved label documents a transient increase in blood pressure and a decrease in heart rate after each dose. Because of that it is contraindicated in people with uncontrolled hypertension and in those with known cardiovascular disease. These are label contraindications based on measured effects, not theoretical cautions.
Yes, and the label says so. Repeated dosing can produce focal hyperpigmentation including on the face, gums and breasts. It is more likely with more frequent dosing and in people with darker skin, and the label notes it may not resolve after discontinuation. The cause is MC1R engagement, the same receptor the Melanotan compounds act on.
Mechanism and site of action. PDE5 inhibitors work peripherally on smooth muscle and blood flow. Bremelanotide acts centrally on melanocortin receptors in the brain, principally MC4R, in pathways related to arousal and motivation rather than vascular tone. That is why its approved indication is a desire disorder rather than a performance one.
Nausea, by a clear margin, and it was common enough in the trials to drive discontinuations. Flushing, headache and injection site reactions follow. Anyone reading the approved label will find nausea listed as the dominant tolerability issue.
Good pairing options with PT-141 Peptide (Bremelanotide)
What researchers stack alongside it.
Pairing is where research gets ahead of itself. These are the compounds researchers put in the same order as PT-141 Peptide (Bremelanotide), which is a statement about ordering habits, not about evidence. Two things in one cart have not been studied together unless somebody studied them together.
Not a molecule. FSH and LH activity extracted from postmenopausal urine and standardised in international units. Still marketed in Canada in 2026, which makes it the rare extract with live approvals.
The unprocessed precursor, all 344 residues with the signal peptide still attached. The protein your body actually secretes is a different animal: 315 residues and 36 cysteines folded just so.
Order PT-141 Peptide (Bremelanotide) right now
One last look before you decide.
Freeze-dried, COA on the page, ships cold
If you are researching PT-141 Peptide (Bremelanotide) and you want a source you do not have to second-guess, start with the paperwork on this page. For research use only.
Not for human consumption. Not approved by Health Canada or any other regulatory body.
Page last updated August 19, 2026
People also search for PT-141 Peptide (Bremelanotide)
Other names for the same compound.